Novavax Announces Topline RSV F Vaccine Data from Two …
WEBSep 25, 2016 · GAITHERSBURG, Md., Sept. 15, 2016 (GLOBE NEWSWIRE) -- Novavax, Inc., (Nasdaq:NVAX) today announced topline data from two clinical trials of its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in older adults.
Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older ...
WEBApr 5, 2023 · The investigational bivalent RSV prefusion F protein−based (RSVpreF) vaccine contains stabilized prefusion F glycoproteins from the two major cocirculating antigenic subgroups (RSV A and...
Efficacy and Safety of an mRNA-Based RSV PreF Vaccine in Older …
WEBDec 13, 2023 · The mRNA-1345 vaccine is a lipid nanoparticle–encapsulated mRNA-based vaccine encoding the membrane-anchored RSV-F glycoprotein, derived from an RSV A strain, and stabilized in the preF...
RSV Prefusion F Protein–Based Maternal Vaccine - The New …
WEBMar 13, 2024 · Vaccination against respiratory syncytial virus (RSV) during pregnancy may protect infants from RSV disease. Efficacy and safety data on a candidate RSV prefusion F protein–based maternal...
Novavax Announces Topline Results from Phase 3 PrepareTM …
WEBFeb 28, 2019 · ResVax™, its RSV vaccine for infants via maternal immunization, is the only vaccine in a Phase 3 clinical program and is designed to prevent severe lower respiratory tract infection which is the second leading cause …
The road to approved vaccines for respiratory syncytial virus
WEBSep 25, 2023 · After decades of work, several interventions to prevent severe respiratory syncytial virus (RSV) disease in high-risk infant and older adult populations have finally been approved.
Profile of respiratory syncytial virus prefusogenic fusion protein ...
WEBDespite over 60 years of research, there is no licensed vaccine for RSV. Areas covered: The primary focus of this review is a novel RSV-F recombinant nanoparticle vaccine from Novavax utilizing the F protein, a conserved and immunodominant surface glycoprotein.
Novavax Vaccine Progress Pipeline | Novavax
WEBOur pipeline. Novavax aims to develop innovative vaccines that may help improve lives and fight infectious diseases around the world. The table below lists our selected research and development priorities. Our Matrix-M adjuvant technology. Investigational vaccines listed below with the Matrix-M symbol have been developed with the Matrix-M adjuvant.
Novavax reports topline RSV F Vaccine data from two clinical …
WEBSep 15, 2016 · Novavax has reported topline data from two clinical trials of its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) in older adults.
WEBIf deployed effectively and equitably, a new generation of respiratory syncytial virus vaccines could help to prevent countless deaths and hospitalizations in the young and old. By Michael...
- Some results have been removed
Skip to content